tnf-a , human

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Tengonermin (ARENEGYR), a vascular-targeting compound, comprises human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. It enhances intratumoral chemotherapy delivery and T-cell infiltration by altering the tumor microenvironment [1] [2].

Lenercept (Ro 45-2081) is a recombinant fusion protein that combines the soluble TNF-receptor (p55) with the Fc portion of human IgG1 [1].

Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19 and has potential applications in treating ARDS related to COVID-19, subject to ongoing research [1].

Mapatumumab (HGS-ETR1) is a fully human agonistic monoclonal antibody targeting TNF-related apoptosis-inducing ligand receptor 1, with anticancer activity, capable of inducing apoptosis in cancer cells.

Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat amyotrophic lateral sclerosis. Atibuclimab reduces LPS-induced disease and inhibits LPS-induced pro-inflammatory cytokine release, delaying the release of anti-inflammatory cytokine soluble TNF receptor type I.

Tavolixizumab (also known as MEDI 0562 and Tavolimab) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4), utilized in cancer immunology studies [1].

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

MEDI-7352 is a human bispecific antibody targeting NGF/bNGF and TNF. It can be utilized in research focused on osteoarthritis (OA) pain.

Anti-Fibronectin Antibody (L19-TNF) is a human-derived antibody expressed in CHO cells, specifically targeting Fibronectin. It has a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 144.14 kDa. For its isotype control, please refer to HumanIgG4kappa, Isotype Control.

ASP8374 is a human IgG4 monoclonal antibody (mAb) that targets TIGIT. This compound enhances IL-2 production in Jurkat cells and increases the production of IFN-γ and TNF-α in human PBMCs. ASP8374 is applicable in research on advanced solid tumors. The recommended isotype control is HumanIgG4kappa, Isotype Control.

VTX-0811 is a human IgG4 monoclonal antibody (mAb) that targets PSGL1/CD162. It modulates immune signaling pathways by enhancing TNF-α/NF-κB and chemokine-mediated signaling while reducing oxidative phosphorylation, fatty acid metabolism, and Myc signaling. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells and exhibits antitumor activity in humanized mouse PDX models of melanoma.

DLX-105 is a human monoclonal antibody (mAb) that targets TNFSF2/TNFa. It reduces epidermal thickness and the expression of K16 and Ki67 in the skin. Additionally, DLX-105 downregulates mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. This compound is useful for psoriasis research.

Afimkibart (PF06480605) is a humanised monoclonal antibody targeting TL1A (TNF-like Ligand 1A), which blocks TL1A-DR3 (death domain receptor 3) signalling on restrictive immune cells and fibroblasts. It can be used for inflammatory bowel disease and ulcerative colitis.

Anti-TNF-alpha Antibody (5Z310) is a Mouse IgG1 monoclonal antibody targeting Human TNF-alpha.

Anti-TNF-alpha Antibody (9S740) is a Rabbit IgG monoclonal antibody targeting Human TNF-alpha.

BI-1808 is a human IgG1 monoclonal antibody targeting TNFR2. It blocks the interaction between TNFR2 and its ligand TNF-α, leading to FcγR-dependent regulatory T cell depletion and facilitating the expansion of intratumoral CD8+ T cells.